These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Amrinone: a promising new cardiotonic agent in the treatment of chronic cardiac failure. Likoff MJ; Weber KT; Andrews V; Janicki JS Herz; 1983 Aug; 8(4):199-205. PubMed ID: 6413341 [No Abstract] [Full Text] [Related]
7. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Stevenson LW Circulation; 2003 Jul; 108(3):367-72. PubMed ID: 12876135 [No Abstract] [Full Text] [Related]
8. [Progress in therapy for chronic heart failure]. Hori M Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():111-5. PubMed ID: 11989248 [No Abstract] [Full Text] [Related]
9. [Efficacy and problems of cardiotonic agents viewed from physiopathology of chronic congestive heart failure]. Asanoi H; Inoue H Nihon Naika Gakkai Zasshi; 1995 Sep; 84(9):1465-9. PubMed ID: 8537751 [No Abstract] [Full Text] [Related]
10. Patients with advanced heart failure and the effects of levosimendan. Song ZZ; Ma J Am J Cardiol; 2007 Aug; 100(4):742; author reply 742-3. PubMed ID: 17697841 [No Abstract] [Full Text] [Related]
11. Vesnarinone for heart failure. Schwartz A; Grupp I; Grupp G N Engl J Med; 1994 Jan; 330(1):65; author reply 66. PubMed ID: 8259153 [No Abstract] [Full Text] [Related]
13. Evaluation of the preoperative vasoactive-inotropic score as a predictor of postoperative outcomes in patients undergoing heart transplantation. Barge-Caballero E; Segovia-Cubero J; González-Vilchez F; Delgado-Jiménez J; Pérez-Villa F; Almenar-Bonet L; Arizón-Del Prado JL; Lage-Gallé E; De La Fuente-Galán L; Manito-Lorite N; Sanz-Julve M; Villa-Arranz A; Lambert Rodríguez JL; Brossa-Loidi V; Pascual-Figal D; Muñiz-García J; Crespo-Leiro M Int J Cardiol; 2015 Apr; 185():192-4. PubMed ID: 25797676 [No Abstract] [Full Text] [Related]
14. When should we use nitrates in congestive heart failure? Vizzardi E; Bonadei I; Rovetta R; D'Aloia A; Quinzani F; Curnis A; Dei Cas L Cardiovasc Ther; 2013 Feb; 31(1):27-31. PubMed ID: 22953723 [TBL] [Abstract][Full Text] [Related]
16. [Digitalis: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects]. Ashizawa N; Yano K Nihon Rinsho; 2007 May; 65 Suppl 5():14-8. PubMed ID: 17569306 [No Abstract] [Full Text] [Related]
17. Medical management of heart failure secondary to coronary artery disease. Challapalli S; Bonow RO; Gheorghiade M Coron Artery Dis; 1998; 9(10):659-74. PubMed ID: 9894618 [No Abstract] [Full Text] [Related]
18. [Calcium sensitizers--a new group of drugs that increase myocardium contractility]. Laine M; Lehtonen L; Nieminen MS Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622 [No Abstract] [Full Text] [Related]
19. [Consensus of experts on the role of ethyl esters of omega-3 polyunsaturated fatty acids for the treatment and prevention of chronic heart failure (conclusion of experts meeting, June 2011)]. Belenkov IuN; Mareev VIu; Arutiunov GP; Shliakhto EV; Koziolova NA; Ageev FT; Tatarskiĭ BA; Lopatin IuM; Fomin IV; Kastanian AA; Ardashev AV; Giliarevskiĭ SR; Moiseev SV; Doshitsin VL; Linchak RM; Kardiologiia; 2011; 51(9):89-91. PubMed ID: 21943014 [No Abstract] [Full Text] [Related]
20. [Effects of a new positive inotropic agent on heart failure of a cardiopulmonary preparation]. Kabela E; Michaels DC; Felice EL Arch Inst Cardiol Mex; 1979; 49(5):892-907. PubMed ID: 398199 [No Abstract] [Full Text] [Related] [Next] [New Search]